Fig. 4
LSD1 specifically mediates CFZ sensitivity. A Inducible KMS-28 TTA_shLSD1-D6 cells were transduced with shRNA-resistant and Myc_tagged LSD1 WT (pLX301_LSD1 WT), catalytically inactive LSD1K661A (pLX301_LSD1K661A), N-terminal lacking LSD1 (pLX304_LSD1ΔN) or empty vector (pLX301_empty, pLX304_empty). Cells were treated or not with DOX (1 µg/ml) and pellets collected after 5 days. LSD1, MycTag and GFP expression were analyzed by western blot. α-tubulin was used for protein loading normalization. B Inducible KMS-28 TTA_shLSD1-D6 cells were pre-treated with DOX (1 µg/ml) for 5 days, then with 2.5 nM CFZ. Cell viability was measured by TMRM staining-flow cytometry 120 h post-CFZ treatment. C, D Indicated cells were treated with SP2577 (2 µM for AMO-1 and RPMI-8226; 4 µM for KMS-28), CC-90011 (20 µM), CFZ (2.5 nM for KMS-28 and RPMI-8226; 5 nM for AMO-1) or the combinations. Cell viability was measured by TMRM staining-flow cytometry 72 hpt. Data are the means ± s.d. of at least three independent experiments. (**P < .01; ***P < .001; ****P < .0001; ns > .05)